Proprietario: Istituto Oncologico Veneto

Innovative vaccine adjuvant which, if chemically conjugated to an antigen, is able to induce a specific and lasting immune response.

Marker to allow the analysis of patients with glioblastoma which can respond positively to the angiogenic drug Regorafenib.

Low toxicity complexes which could find therapeutic use in the case of tumors with high NOTCH expression.